Summary
We have utilized a recently developed human tumor cloning system to screen for antitumor effects in vitro of a new anthracene derivative, CL216,942. The object was to determine whether the system is useful for pinpointing the types of tumors in patients which should be studied in early phase II clinical trials. Tumors from 684 patients were placed in culture (27 different histologic tumor types). Two hundred seventy-three tumors both grew and formed enough colonies for drug sensitivity assays. In vitro antitumor activity was noted for CL216,942 against human breast cancer, ovarian cancer, renal cancer, squamous cell, small cell and large cell lung cancer, lymphoma, acute myelogenous leukemia, melanoma, adenocarcinoma of unknown origin, adrenal cancer, gastric cancer, pancreatic cancer, and head and neck cancer. The drug definitely showed no in vitro activity against colon cancer. These date indicate that CL216,942 has a wide spectrum of in vitro antitumor activity. A comparison of these in vitro results with the results of phase II clinical trials with the drug should allow an evaluation of the utility of the human cloning system for predicting clinical activity of a new compound.
Similar content being viewed by others
References
Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE (1980) Anti-tumor activity of CL216,942: 9,10 Anthracenedicarboxaldehyde bis ((4,5-dihydro-1 H-imidazol-2-yl)hydrazone)dihydrochloride. Abstracts of the 20th Interscience Conference on Antimicrobial agents and Chemotherapy. (Abstract no. 23)
Hamburger AW, Salmon SE (1977a) Primary bioassay of human tumor stem cells. Science 197: 461–463
Hamburger AW, Salmon SE (1977b) Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846–854
Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327
Salmon SE, Alberts D, Meyskens F, Durie B, Jones S, Soehnlen B, Young L (1980) A new concept: In vitro phase II trial with the human tumor stem cell assay (HTSCA). Proc Am Assoc Cancer Res/ASCO 21: 329
Von Hoff DD, Rozencweig M, Muggia FM (1979) The evaluation of cytotoxic drugs. Cancer Treat Rev 6: 1–8
Von Hoff DD, Coltman CA Jr, Forseth B (1981a) Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41: 1853–1855
Von Hoff DD, Casper J, Bradley F, Sandbach J, Jones D, Makuch R (1981b) Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70: 1027–1032
Von Hoff DD, Page C, Harris G, Clark G, Cowan J, Coltman CA Jr (1981c) Prospective clinical trial of a human tumor cloning system. Proc Am Assoc Cancer Res 22: 154
Von Hoff DD, Myers JW, Kuhn J, Sandbach JR, Pocelinko R, Clark G, Coltman CA Jr (1981d) Phase I clinical investigation of 9–10 anthracenedicarboxaldehyde bis ((4,5-dihydro-1 H-imidazol-2-yl)hydrazone) dihydrochloride (CL-216,942). Cancer Res 41:3118–3121
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Von Hoff, D.D., Coltman, C.A. & Forseth, B. Activity of 9–10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system. Cancer Chemother. Pharmacol. 6, 141–144 (1981). https://doi.org/10.1007/BF00262332
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262332